[1]张文娟,边 伟,王炳超,等.miR-381在胰腺癌患者组织及外周血的表达及临床价值[J].医学信息,2021,34(06):111-114.[doi:10.3969/j.issn.1006-1959.2021.06.028]
　ZHANG Wen-juan,BIAN Wei,WANG Bing-chao,et al.The Expression and Clinical Value of miR-381 in Tissues and Peripheral Blood of Patients with Pancreatic Cancer[J].Medical Information,2021,34(06):111-114.[doi:10.3969/j.issn.1006-1959.2021.06.028]
点击复制

miR-381在胰腺癌患者组织及外周血的表达及临床价值()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年06期
页码:
111-114
栏目:
论著
出版日期:
2021-03-15

文章信息/Info

Title:
The Expression and Clinical Value of miR-381 in Tissues and Peripheral Blood of Patients with Pancreatic Cancer
文章编号:
1006-1959（2021）06-0111-04
作者:
张文娟; 边 伟; 王炳超; 等
（1.邯郸市第一医院消化科，河北 邯郸 056002； 2.河北医科大学第二医院普外一科，河北 石家庄 050000； 3.邯郸市第一医院普外二科，河北 邯郸 056002）
Author(s):
ZHANG Wen-juan; BIAN Wei; WANG Bing-chao; et al.
(1.Department of Gastroenterology,Handan First Hospital,Handan 056002,Hebei,China; 2.The First Department of General Surgery,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China; 3.The Second Department of General Surgery,Handan First Hospital,Handan 056002,Hebei,China)
关键词:
胰腺癌; 组织; 血清; miR-381; 肿瘤标志物
Keywords:
Pancreatic cancer; Tissue; Serum; miR-381; Tumor marker
分类号:
R735.9；R730.2
DOI:
10.3969/j.issn.1006-1959.2021.06.028
文献标志码:
A
摘要:
目的 探究miR-381在胰腺癌组织及外周血中的表达。方法 选取2017年7月~2018年8月邯郸市第一医院及河北医科大学第二医院确诊的50例胰腺癌患者的组织及外周血清，另外选取患者的癌旁正常组织及同期50例健康体检者血清样本作为对照组。采用RT-qPCR技术检测胰腺癌组织、血清和健康者血清中miR-381的表达水平，分析miR-381的表达水平与胰腺癌患者临床病理特征的关系，评价miR-381诊断胰腺癌的价值。结果 胰腺癌组织及血清中miR-381的表达低于对照组，差异有统计学意义（P＜0.05）；不同肿瘤分期、淋巴结转移的胰腺癌患者miR-381的表达比较，差异有统计学意义（P＜0.05）；不同性别、年龄的胰腺癌患者miR-381的表达比较，差异无统计学意义（P＞0.05）；胰腺癌组织miR-381诊断胰腺癌的敏感性、特异性为84.51%及80.34%，胰腺癌血清miR-381诊断胰腺癌的敏感性、特异性为82.31%及81.26%。结论 miR-381在胰腺癌组织及血清中呈低表达，其参与了胰腺癌的发生发展，可作为新的潜在肿瘤标志物。
Abstract:
Objective To explore the expression of miR-381 in pancreatic cancer tissues and peripheral blood.Methods The tissues and peripheral serum of 50 patients with pancreatic cancer diagnosed in Handan First Hospital and the Second Hospital of Hebei Medical University from July 2017 to August 2018 were selected.In addition, 50 cases of normal tissues adjacent to cancer and 50 cases of healthy subjects were selected as the control group during the same period.RT-qPCR technology was used to detect the expression level of miR-381 in pancreatic cancer tissue, serum and serum of healthy individuals, analyze the relationship between the expression level of miR-381 and the clinicopathological characteristics of patients with pancreatic cancer, and evaluate the value of miR-381 in the diagnosis of pancreatic cancer.Results The expression of miR-381 in pancreatic cancer tissue and serum was lower than that in the control group,the difference was statistically significant (P＜0.05);The expression of miR-381 in pancreatic cancer patients with different tumor stages and lymph node metastasis was compared,the difference was statistically significant (P<0.05);There was no statistically significant difference in the expression of miR-381 in pancreatic cancer patients of different genders and ages (P>0.05);The sensitivity and specificity of pancreatic cancer tissue miR-381 in diagnosing pancreatic cancer were 84.51% and 80.34%, and the sensitivity and specificity of pancreatic cancer serum miR-381 in diagnosing pancreatic cancer were 82.31% and 81.26%.Conclusion miR-381 is low expressed in pancreatic cancer tissues and serum. It is involved in the occurrence and development of pancreatic cancer and can be used as a new potential tumor marker.

参考文献/References:

[1]Ferlay J,Colombet M,Soerjomataram I,et al.Cancer incidence and mortality patterns in Europe:Estimates for 40 countries and 25 major cancers in 2018[J].European Journal of Cancer,2018(103):356-387. [2]陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13. [3]Kleeff J,Korc M,Apte M,et al.Pancreatic cancer[J].Nature Reviews Disease Primers,2016,2(5):16022. [4]Solomon MC,Radhakrishnan RA.MicroRNA’s-The vibrant performers in the oral cancer scenario[J].The Japanese Dental Science Review,2020,56(1):85-89. [5]Ghafouri-Fard S,Vafaee R,Shoorei H,et al.MicroRNAs in gastric cancer:Biomarkers and therapeutic targets[J].Gene,2020(757):144937. [6]Wang C,Yin W,Liu H.MicroRNA-10a promotes epithelial-to-mesenchymal transition and stemness maintenance of pancreatic cancer stem cells via upregulating the Hippo signaling pathway through WWC2 inhibition[J].Journal of Cellular Biochemistry,2020,121(11):4505-4521. [7]Zhu J,Lv J,Chen J,et al.Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation[J].Cell Cycle,2020,19(21):2851-2865. [8]杨尹默.AJCC第八版及日本胰腺学会第七版胰腺癌TNM分期的更新要点及内容评介[J].中华外科杂志,2017,55(1):20-23. [9]Li R,Pu X,Chang JY,et al.miRNAs-related genetic variations associated with radiotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer[J].PLoS One,2016,11(3):e0150467. [10]Zhai W,Li S,Zhang J,et al.Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals[J].Molecular Cancer,2018,17(1):157. [11]Tuncer SB,Erdogan OS,Erciyas SK,et al.miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma:potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma[J].Journal of ovarian research,2020,13(1):99. [12]Erdmann K,Salomo K,Klimova A,et al.Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer[J].International Journal of Molecular Sciences,2020,21(11):3814. [13]Beylerli O,Beeraka NM,Gareev I,et al.MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas[J].International Journal of Molecular Sciences,2020,21(19):7287. [14]Aboutalebi H,Bahrami A,Soleimani A,et al.The diagnostic,prognostic and therapeutic potential of circulating microRNAs in ovarian cancer[J].The International Journal of Biochemistry&Cell Biology,2020,124(4):105765. [15]Formosa A,Markert EK,Lena AM,et al.MicroRNAs,miR-154,miR-299-5p,miR-376a,miR-376c,miR-377,miR-381,miR-487b,miR-485-3p,miR-495 and miR-654-3p,mapped to the 14q32.31 locus,regulate proliferation,apoptosis,migration and invasion in metastatic prostate cancer cells[J].Oncogene,2014,33(44):5173-5182. [16]Zhang M,Huang S,Long D.MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4[J].Oncology Letters,2017,14(3):3760-3766. [17]Yang X,Ruan H,Hu X,et al.miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2[J].American Journal of Cancer Research,2017,7(4):913-922. [18]Xue Y,Xu W,Zhao W,et al.miR-381 inhibited breast cancer cells proliferation,epithelial-to-mesenchymal transition and metastasis by targeting CXCR4[J].Biomed Pharmacother,2017(86):426-433. [19]Zhang Q,Zhao S,Pang X,et al.MicroRNA-381 suppresses cell growth and invasion by targeting the liver receptor homolog-1 in hepatocellular carcinoma[J].Oncology Reports,2016,35(3):1831-1840. [20]蒋林涛,蔡钧,杨世疆,等.miR-381对胰腺癌细胞增殖、迁移和侵袭的影响及机制[J].华中科技大学学报（医学版）,2018,47(2):188-192. [21]Qiao G,Li J,Wang J,et al.miR?381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer[J].International Journal of Molecular Medicine,2019,44(2):593-607. [22]Kim H,Kim T,Jaygal G,et al.Downregulation of miR-9 correlates with poor prognosis in colorectal cancer[J].Pathology,Research and Practice,2020,216(8):153044. [23]Elhendawy M,Abdul-Baki EA,Abd-Elsalam S,et al.MicroRNA signature in hepatocellular carcinoma patients:identification of potential markers[J].Molecular Biology Reports,2020,47(7):4945-4953.

相似文献/References:

[1]孙惠昕,贾海晗,王婉莹,等.胰腺癌流行现状和影响因素的研究[J].医学信息,2022,35(11):47.[doi:10.3969/j.issn.1006-1959.2022.11.014]
　SUN Hui-xin,JIA Hai-han,WANG Wan-ying,et al.The Prevalence and Influencing Factors of Pancreatic Cancer[J].Medical Information,2022,35(06):47.[doi:10.3969/j.issn.1006-1959.2022.11.014]
[2]赵霓姗.胰腺癌主要危险因素及作用机制研究[J].医学信息,2020,33(03):56.[doi:10.3969/j.issn.1006-1959.2020.03.017]
　ZHAO Ni-shan.Study on the Main Risk Factors and Mechanism of Pancreatic Cancer[J].Medical Information,2020,33(06):56.[doi:10.3969/j.issn.1006-1959.2020.03.017]
[3]周国斌,柳登平.磁共振和经腹部彩超对胰腺癌与肿块型胰腺炎的鉴别诊断价值分析[J].医学信息,2022,35(17):99.[doi:10.3969/j.issn.1006-1959.2022.17.026]
　ZHOU Guo-bin,LIU Deng-ping.Value of Magnetic Resonance and Transabdominal Ultrasonography in Differential Diagnosis of Pancreatic Carcinoma and Mass-type Pancreatitis[J].Medical Information,2022,35(06):99.[doi:10.3969/j.issn.1006-1959.2022.17.026]
[4]漆处梅,唐小龙.胰腺癌患者BZW1和BZW2表达水平及其与预后的相关性分析[J].医学信息,2022,35(21):26.[doi:10.3969/j.issn.1006-1959.2022.21.006]
　QI Chu-mei,TANG Xiao-long.Expression of BZW1 and BZW2 in Pancreatic Cancer and its Correlation with Prognosis[J].Medical Information,2022,35(06):26.[doi:10.3969/j.issn.1006-1959.2022.21.006]
[5]王雨娜,吴冬桂,赵 贝.基于数据挖掘AGR2在胰腺癌中的表达及预后潜力[J].医学信息,2022,35(22):9.[doi:10.3969/j.issn.1006-1959.2022.22.002]
　WANG Yu-na,WU Dong-gui,ZHAO Bei.Expression and Prognostic Potential of AGR2 in Pancreatic Cancer Based on Data Mining[J].Medical Information,2022,35(06):9.[doi:10.3969/j.issn.1006-1959.2022.22.002]
[6]王宇路,王苏平,赵雪梅,等.磁共振胰胆管成像对肿块型胰腺炎与胰腺癌的诊断价值[J].医学信息,2021,34(13):176.[doi:10.3969/j.issn.1006-1959.2021.13.049]
　WANG Yu-lu,WANG Su-ping,ZHAO Xue-mei,et al.The Value of Magnetic Resonance Cholangiopancreatography in the Differential Diagnosis of Mass Forming ChronicPancreatitis and Pancreatic Cancer[J].Medical Information,2021,34(06):176.[doi:10.3969/j.issn.1006-1959.2021.13.049]
[7]刘 基,孙振纲,邓 岩,等.炎症对胰腺癌患者预后的评估及免疫状态的影响[J].医学信息,2023,36(05):13.[doi:10.3969/j.issn.1006-1959.2023.05.003]
　LIU Ji,SUN Zhen-gang,DENG Yan,et al.Effects of Inflammation on Prognosis and Immune Status in Patients with Pancreatic Adenocarcinoma[J].Medical Information,2023,36(06):13.[doi:10.3969/j.issn.1006-1959.2023.05.003]
[8]邓裕山,沈国双.AP1基因家族与恶性肿瘤的关系研究[J].医学信息,2022,35(06):56.[doi:10.3969/j.issn.1006-1959.2022.06.014]
　DENG Yu-shan,SHEN Guo-shuang.Study on the Relationship Between AP1 Gene Family and Malignant Tumors[J].Medical Information,2022,35(06):56.[doi:10.3969/j.issn.1006-1959.2022.06.014]
[9]石 磊,任婷婷,谭 云,等.基于TOUS胰腺癌术后患者症状群与CRF、生活质量的研究[J].医学信息,2024,37(12):179.[doi:10.3969/j.issn.1006-1959.2024.12.041]
　SHI Lei,REN Ting-ting,TAN Yun,et al.Study on Symptom Clusters, CRF and Quality of Life of Postoperative Patients with Pancreatic Cancer Based on TOUS[J].Medical Information,2024,37(06):179.[doi:10.3969/j.issn.1006-1959.2024.12.041]
[10]卢 琪,尹富生,兰 凯.PI3K/AKT/mTOR通路与胰腺癌发生发展及治疗的研究[J].医学信息,2025,38(02):184.[doi:10.3969/j.issn.1006-1959.2025.02.037]
　LU Qi,YIN Fusheng,LAN Kai.Role of PI3K/AKT/mTOR Pathway in the Development and Treatment of Pancreatic Cancer[J].Medical Information,2025,38(06):184.[doi:10.3969/j.issn.1006-1959.2025.02.037]

更新日期/Last Update: 1900-01-01